Company Filing History:
3 out of 1,721 
2 out of 29 
1 out of 184 
Years Active: 2021-2025
Title: Mark Pykett: Innovator in Gene Therapy
Introduction
Mark Pykett is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of gene therapy, particularly in the treatment of rare genetic disorders. With a total of 5 patents to his name, Pykett's work is paving the way for innovative therapeutic solutions.
Latest Patents
One of Pykett's latest patents focuses on gene therapy for aromatic-amino acid decarboxylase (AADC) deficiency. This invention outlines compositions and methods for treating AADC deficiency, particularly in pediatric subjects. The method involves providing a pharmaceutical formulation comprising an rAAV2-hAADC vector and delivering it stereotactically to target sites in the brain. The patent also discusses the potential administration of a dopamine-antagonist, such as risperidone, to enhance treatment efficacy. Another notable patent involves frataxin expression constructs, which provide polynucleotides, vectors, and viruses expressing frataxin, aimed at treating Friedreich's Ataxia.
Career Highlights
Throughout his career, Mark Pykett has worked with esteemed institutions, including National Taiwan University and Precigen, Inc. His innovative research has garnered attention in the scientific community, contributing to advancements in gene therapy.
Collaborations
Pykett has collaborated with notable colleagues, including Richard M Thorn and Wuh-Liang (“Paul”) Hwu. These partnerships have further enriched his research and development efforts in the field of gene therapy.
Conclusion
Mark Pykett's contributions to gene therapy exemplify the impact of innovative thinking in addressing complex medical challenges. His work continues to inspire advancements in the treatment of genetic disorders.